2 Growth Stocks to Buy Hand Over Fist in February

Group 1: Eli Lilly - Eli Lilly has shown strong performance over the past five years, with revenue growth exceeding 20% year over year for the last six quarters [2][3] - The company has a robust product lineup, including diabetes and weight loss medications Mounjaro and Zepbound, although recent sales growth has not met analyst expectations [3][4] - Eli Lilly is actively innovating, with promising candidates in its pipeline, including a gene therapy for deafness and a late-stage weight loss treatment called retatrutide [4][5] - The company has increased its dividend payouts by nearly 103% over the past five years, making it an attractive option for both growth and income investors [6] Group 2: Sarepta Therapeutics - Sarepta Therapeutics focuses on developing treatments for rare diseases, particularly Duchenne muscular dystrophy, with several drugs already on the market [7] - The key product, Elevidys, received full FDA approval for ambulatory patients and accelerated approval for non-ambulatory patients, significantly boosting the company's financial performance [8][9] - Sarepta Therapeutics anticipates net revenue of $1.8 billion in 2024, a 49$1.2 billion in 2023, driven by Elevidys and other pipeline candidates [10] - The company has over 40 candidates in its pipeline, including therapies for Limb-Girdle muscular dystrophy, positioning it for strong long-term growth [11]